Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BLIRT S.A. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, KOROTCHKINA, LIOUBOV G, who is also identified as the busiest examiner with 1 pending application. The concentration of the portfolio is further evidenced by its presence in 1 distinct art unit.
For practitioners, this indicates a focused prosecution effort where all current interactions are centralized under 1 distinct examiner. This 1 to 1 ratio between pending actions and examiners suggests that the company's immediate patent strategy is contained within a specific technical niche. Monitoring the progress of this 1 pending office action is critical for the development of the Biotechnology & Pharmaceuticals portfolio.
The reliance on 1 distinct art unit and 1 distinct examiner, KOROTCHKINA, LIOUBOV G, means that the company's success depends on a single administrative path. With 1 pending application, the company can focus its resources on meeting the specific requirements of the patent office. This streamlined structure simplifies the management of the company's active intellectual property matters at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | 1653 | §103§112Other | Non-Final OA | — | Pending | Mar 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial